Assessment of myocardial damage in dilated cardiomyopathy
See page 545 for the article to which this Editorial refers Dilated cardiomyopathy is associated with impairment of systolic function. Damage to cardiac myocytes, including disruption of the sarcolemma, can be demonstrated by enhanced myocardial binding of monoclonal antibody to cardiac myosin in a large proportion of patients with dilated cardiomyopathy. Binding of an '"in-labelled Fab fragment of antimyosin antibody to myocardium can be quantitated by scintigraphy and compared to uptake by other tissue such as lung. This heart-to-lung ratio has been used to assess the degree of myocardial damage in patients with acute inflammation resulting from myocardial infarction, myocarditis or rejection of the transplanted heart 1 ' 1 . The histological changes in dilated cardiomyopathy are nonspecific and similar to those in patients with end-stage heart failure from causes such as valve disease, hypertensive heart disease or coronary heart disease. Unlike patients with dilated cardiomyopathy, however, enhanced uptake of antimyosin is not seen in end-stage heart failure due to these other causes.
Enterovirus infection of myocardium has been shown to be associated with myocarditis and the subsequent progression to dilated cardiomyopathy* 
Preconditioning of the heart

See page 539 for the article to which this Editorial refers
The paper by Claeys and co-workers in this issue 1 ' 1 draws attention to the important phenomenon of ischaemic preconditioning. This subject has been extensively investigated after the first description by Murry et al. in 1986' 21 . In the canine heart, ischaemic preconditioning could be induced by a short period (about 5 min) of ischaemia followed by a period of less than 60-120 min of reperfusion, prior to the actual period of ischaemia, which then caused less damage than was observed in the absence of preconditioning ischaemia. Also, multiple periods of 5 min of ischaemia, each followed by 5 min of reperfusion, induced preconditioning. Ischaemic preconditioning was observed in hearts of several animal species, and proved to be independent of a rapidly recruitable collateral circulation. Preconditioning could also be induced by measures other than coronary occlusion provided the myocardial supply/demand ratio was compromised.
From 1990 onwards, several groups have collected evidence that ischaemic preconditioning may also occur in the human heart. In the Thrombolysis In Myocardial Infarction (TIMI)-4 trial, patients who had a history of previous angina at any time before acute myocardial infarction, had lower in-hospital mortality, experienced congestive heart failure or shock less frequently, and had smaller enzymatic infarct sizes than patients without a history of previous angina'
31
. At open heart surgery, Yellon et al. demonstrated that brief episodes of aortic crossclamping followed by reperfusion prior to construction of coronary artery bypass grafts resulted in a reduced decrease of adenosine triphosphate concentrations after cross-clamping for construction of the proximal anastomoses' 41 . Balloon occlusion during percutaneous transluminal coronary angioplasty (PTCA) provides a suitable clinical model with which to study preconditioning in vivo. In accordance with the observations of Claeys et a/.' 11 several investigators have demonstrated that initial repeated balloon inflations followed by reperfusion led to diminished signs of ischaemia during PTCA. However, these observations rely to a large extent on the magnitude of ST elevations which may be influenced by other (metabolic) factors than ischaemia. In addition, in spite of a careful selection of cases the possibility of changes in collateral flow cannot be excluded. Therefore, we must conclude that the results of these clinical studies in man are compatible with a protective effect due to myocardial preconditioning, but cannot be considered to be definite proof of a unique phenomenon.
Interestingly, 'ischaemic preconditioning' of the heart can be induced by several pharmacological compounds. The working hypothesis has emerged that adenosine formed by degradation of adenosine triphosphate during the first period of ischaemia and liberated by ischaemic myocytes, acts as an autocoid and binds to adenosine A,-receptors on the sarcolemmal membrane 151 . A beneficial response is elicited which protects the myocyte against a second period of ischaemia. Infusion of adenosine or adenosine A|receptor agonists could, indeed, diminish myocardial damage of the ischaemic heart' 61 . Likewise,
